Roadmap for access 2019-2023
Comprehensive support for access to medicines and vaccines

Informal Discussion with Stakeholders
10 September 2018, Geneva
Background

**WHC 71**

**DG’s Report**

Report by the Director-General on addressing the global shortage of, and access to, medicines and vaccines. The report focused on a list of priority options for actions to be considered by Member States and presented a comprehensive report by the Director-General on access to essential medicines and vaccines Document A71/12.

**WHC 71 (8) Decision**

1) elaborate a roadmap report, in consultation with Member States, outlining the programming of WHO’s work on access to medicines and vaccines, including activities, actions and deliverables for the period 2019–2023

(2) submit this roadmap report to the Seventy-second World Health Assembly for its consideration in 2019, through the Executive Board at its 144th session.
## How the roadmap was developed

<table>
<thead>
<tr>
<th>Activity</th>
<th>Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specific Actions</td>
<td>Improving alignment with various global, regional and organizational strategic documents.</td>
</tr>
<tr>
<td>Deliverables</td>
<td></td>
</tr>
</tbody>
</table>

**Specific Actions**
- Improving alignment with various global, regional and organizational strategic documents.
10 Activity Areas

Roadmap for access 2019-2023

Comprehensive support for access to medicines and vaccines

1. Research and development for medicines and vaccines that meets public health needs
2. Fair pricing and financing policies
3. Application and management of intellectual property to contribute to innovation and promote public health
4. Procurement and supply chain management
5. Appropriate prescribing, dispensing and use
6. Regulatory systems that ensure quality, safety and efficacy of medicines and vaccines
7. Preparedness for emergencies
8. Good governance
9. Collecting, monitoring and using key data
10. Health workforce capacity for access to medicines and vaccines
Total number of countries per region

<table>
<thead>
<tr>
<th>Regions</th>
<th>Number of countries</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFRO</td>
<td>13</td>
</tr>
<tr>
<td>EMRO</td>
<td>4</td>
</tr>
<tr>
<td>EURO</td>
<td>21</td>
</tr>
<tr>
<td>PAHO</td>
<td>10</td>
</tr>
<tr>
<td>SEARO</td>
<td>5</td>
</tr>
<tr>
<td>WPRO</td>
<td>4</td>
</tr>
</tbody>
</table>

Summary

Total number of focal points nominated = 72 countries

Number of completed surveys (as of 31st August 2018) = 56 countries

Additional written feedback = 4 countries
### Contributions received by member states

#### AFRO
1. Burundi
2. Cameroon
3. Central African Republic
4. Congo DRC
5. Cabo verde
6. Ethiopia
7. Mali
8. Mauritius
9. Liberia
10. Seychelles
11. Sierra Leone
12. Tanzania
13. Zambia

#### EURO
1. Austria
2. Albania
3. Belgium
4. Bulgaria
5. Croatia
6. Cyprus
7. Czech Republic
8. Estonia
9. France
10. Finland
11. Georgia
12. Germany*
13. Latvia
14. Italy
15. Malta
16. Norway
17. Portugal
18. Romania
19. Switzerland
20. Ukraine
21. United Kingdom*
22. Uzbekistan

#### PAHO
1. Brazil
2. Chile
3. Canada
4. Ecuador
5. El Salvador
6. Guyana
7. Panama
8. Peru
9. Nicaragua
10. United States

#### EMRO
1. Lebanon
2. Morocco
3. Saudi
4. Syria

#### SEARO
1. Bhutan
2. Maldives
3. Nepal
4. Sri Lanka
5. India*
6. Thailand

#### WPRO
1. Australia
2. China
3. Japan
4. New Zealand

* written comments received from countries
General comments in Roadmap for access 2019-2023

1. Expand the scope to include other medical health products (e.g. in vitro diagnostics) in addition to medicines and vaccines.

2. Enhance collaboration with other UN Agencies, international organizations and non-state actors on the different areas of work.

3. Highlight the importance of strategic and sustainable local production in enhancing availability of medical health products

4. Ensure alignment of timeframes with wider WHO planning efforts such as Programme, Budget and Administration Committee

5. Provide clarity on timelines and prioritization of activities and their respective deliverables, based on an analysis of the greatest needs and potential impact.

6. A number of good examples practices were received
Activity areas generally supported

- Good governance
- Appropriate prescribing, dispensing and use
- Procurement and supply chain
- Regulatory systems that ensure quality, safety and efficacy of medicines and vaccines
Activity areas with most comments

- Preparedness for emergencies
- Fair pricing and financing policies
- Application and management of intellectual property
# Zero Draft - Participation and Consultative Process

<table>
<thead>
<tr>
<th>ACTIVITY</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member States Online Consultation, including good practices examples</td>
<td>9 July- 16 August 2018</td>
</tr>
<tr>
<td>Member States Consultation – Geneva (HQ)</td>
<td>10-11 September 2018</td>
</tr>
<tr>
<td>Informal Discussion with Stakeholders</td>
<td>10 September 2018</td>
</tr>
<tr>
<td>(Collaboration Centers, Partners and NSA in official relations with WHO and UN and related organizations)</td>
<td>(9:00-12:30) EB Room</td>
</tr>
</tbody>
</table>

**ROADMAP DISCUSSIONS - REGIONAL COMMITTEES**

| AFRO (Dakar, Senegal)                                               | 27-31 August                              |
| SEARO (New Delhi) (Ministerial Declaration)                         | 3-7 September                             |

**REVISION OF ROADMAP REPORT**

| Revised version/ 144 EB Secretariat’s report                        | December 2018                             |

**GOVERNING BODIES 2019**

| 144 EB                                                               | January 2019                              |
| 72 WHA                                                               | May 2019                                  |